Discovery and preclinical characterization of ISM8001, a covalent and selective FGFR2/FGFR3 dual inhibitor with strong monotherapy anti-tumor activity against advanced solid tumors

被引：0
|
作者：
Zhang, Yihong
Wang, Yazhou
Cai, Xin
Liu, Jinxin
Cui, Hui
Qiao, Junwen
Lin, Xiaoxia
Ding, Xiao
Bavadekar, Supriya
Rao, Sujata
Zhang, Man
Ren, Feng
Zhavoronkov, Alex
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5582
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5582
引用
收藏
页数：2
相关论文
共 14 条
  • [1] Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors
    Li, Gary
    Krook, Melanie
    Roychowdhury, Sameek
    Avogadri, Francesca
    Ye, Yining
    Moran, Susan
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)
    Tran, B.
    Boni, A.
    Hansen, A.
    Boni, V.
    Mantia, C.
    Yu, E.
    Weickhardt, A.
    Robert, M.
    Gupta, S.
    Necchi, A.
    Morales-Barrera, R.
    Hoimes, C.
    Berlin, J.
    Iyer, G.
    Millward, M.
    Burn, T.
    Lihou, C.
    Gammon, G.
    Rosenberg, J.
    Loriot, Y.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S175 - S175
  • [3] Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
    Tyhonas, John S.
    Arnold, Lee D.
    Cox, Jason M.
    Franovic, Aleksandra
    Gardiner, Elisabeth
    Grandinetti, Kathryn
    Kania, Robert
    Kanouni, Toufike
    Lardy, Matthew
    Li, Chun
    Martin, Eric S.
    Miller, Nichol
    Mohan, Adithi
    Murphy, Eric A.
    Perez, Michelle
    Soroceanu, Liliana
    Timple, Noel
    Uryu, Sean
    Womble, Scott
    Kaldor, Stephen W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (03) : 1734 - 1746
  • [4] BRAF kinase inhibitor exerts anti-tumor activity against breast cancer cells via inhibition of FGFR2
    Zhang, Zong Xin
    Jin, Wen Jun
    Yang, Sheng
    Ji, Cun Li
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (05): : 1040 - +
  • [5] Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
    Schram, Alison M.
    Subbiah, Vivek
    Liao, Chih-Yi
    Moreno, Victor
    Desamparados, Roda
    Ponz-Sarvise, Mariano
    Dotan, Efrat
    Cassier, Philippe Alexandre
    Moreno, Irene
    Varkaris, Andreas
    Kim, Richard D.
    Garralda, Elena
    Opdam, Frans
    Tai, David
    Italiano, Antoine
    Oh, Do-Youn
    Goyal, Lipika
    Fontana, Elise
    Liu, Jia
    Boukovala, Myrto
    Ghiringelli, Francois
    Borad, Mitesh J.
    Babiker, Hani
    Jin, Zhaohui
    Millward, Michael
    Yachnin, Jeffrey
    Kamath, Suneel Deepak
    Coward, Jermaine M.
    Yoo, Changhoon
    Kelley, Robin Kate
    Sahai, Vaibhav
    Bridgewater, John
    Springfield, Christoph
    Florou, Vaia
    El-Khoueiry, Anthony
    Eskens, Ferry
    Lin, Bruce
    Paulson, Scott
    Curigliano, Giuseppe
    Murphy, Meredith
    Deary, Alicia
    Ricard, Fabien
    Jen, Kai Yu
    Ramirez, Florence
    Blakesley, Rick E.
    Schmidt-Kittler, Oleg
    Mar, Brenton G.
    Park, Joon Oh
    Hollebecque, Antoine
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [6] Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study
    Hollebecque, A.
    Dotan, E.
    Liao, C. Y. A.
    Roda, D.
    Fontana, E.
    Babiker, H.
    Kim, R. D.
    Oh, D. Y.
    Ghiringhelli, F.
    Moreno, I.
    Liu, J.
    Subbiah, V.
    Varkaris, A.
    Borad, M. J.
    Cassier, P. A.
    Deary, A.
    Ramirez, F. T.
    Ricard, F.
    Jen, K. Y.
    Schram, A. M.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S24 - S26
  • [7] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Garmezy, B.
    Borad, M.
    Lin, C. C.
    Chen, L. T.
    Perez, C. A.
    Kato, S.
    Tam, B.
    Severson, P.
    Quah, C. S.
    Harding, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S231 - S232
  • [8] Phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Harding, J.
    Perez, C.
    Kato, S.
    Sharma, M.
    Garmezy, B.
    Quah, C.
    Tam, B.
    Severson, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S63 - S64
  • [9] Preclinical evaluation of eFT226, a potent and selective eIF4A inhibitor with anti-tumor activity in FGFR1,2 and HER2 driven cancers
    Thompson, Peggy A.
    Young, Nathan P.
    Gerson-Gurwitz, Adina
    Eam, Boreth
    Goel, Vikas
    Stumpf, Craig R.
    Chen, Joan
    Parker, Gregory S.
    Fish, Sarah
    Barrera, Maria
    Sung, Eric
    Staunton, Jocelyn
    Chiang, Gary G.
    Webster, Kevin R.
    CANCER RESEARCH, 2020, 80 (16)
  • [10] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
    Harding, James J.
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Garmezy, Benjamin
    Quah, Cheng Seok
    Tam, Betty
    Severson, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS637 - TPS637
12